A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients

NCT00625274 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Heartburn
Upper Abdominal Pain
Nausea
Acid Regurgitation

Interventions

DRUG: Esomeprazole
DRUG: Lansoprazole
DRUG: Pantoprazole

Sponsor

AstraZeneca